Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 1875
Special Issue Editors
Interests: immunopathogenesis of human disease; immunoregulation in malignancies; immunotherapy of neoplasms
Special Issues, Collections and Topics in MDPI journals
Interests: leukemia; lymphoma; multiple myeloma; immunopathogenesis
Special Issue Information
Dear Colleagues,
Despite advances in the understanding of hematological malignancies’ pathophysiology, the treatment of hematological neoplasms remains challenging, and the clinical prognosis can be extremely poor despite chemotherapy and bone marrow transplants. Discoveries of novel genetic mutations, critical signaling pathways, and unique biomarkers expressed on the surfaces of leukemic cells or intracellularly have been under investigation for the management of hematological malignancies. Although several new options for the treatment of lymphoproliferative disorders have been approved in the last few years, many of them remain incurable. Improving the therapeutic efficacy of existing therapies or developing a novel therapeutic agent is urgently needed. This Special Issue of Biomedicines, titled “Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches” will include reviews that describe novel strategies for treating hematological malignancies developed over the past few years as well as original research articles that describe novel discoveries in the pathophysiology of hematological neoplasms and strategies for treating hematological malignancies using preclinical and/or translational studies. In addition, studies on biomarkers, combination therapy, drug responses, the tumor microenvironment, and mechanistic approaches will be accepted.
Prof. Dr. Jacek Tabarkiewicz
Guest Editor
Dr. Norbert Grząśko
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematological malignancies
- leukemia
- lymphoma
- myeloma
- chemotherapy
- immunotherapy
- bioactive compounds
- molecular mechanisms
- cellular therapy
